# A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

> **NCT04982237** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Akeso** · enrollment: 445 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **BIOLOGICAL:** AK104
- **DRUG:** paclitaxel
- **DRUG:** carboplatin
- **DRUG:** cisplatin
- **DRUG:** bevacizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04982237
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-27
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 445 (ACTUAL)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04982237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04982237, "A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04982237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*